Table 2 . Ewing’s sarcoma Phase I Demographics Vigil MC* Tumor Location Harvest (Lung/Soft Tissue/Other) 13/0/3 11/2/1 Sex (M/F) 12/4 7/7 Age median (range) 19 (59 -12) 17 (30 -12) Ethnicity (Caucasian/Other) 13/3 12/2 Prior Systemic Treatment (Frontline/2nd/≥3rd) 1/5/10 3/4/7 Surgical Candidate (Yes/No) 16/0 14/0 Tissue Harvested (Yes/No) 16/0 14/0 * Matched Control (MC); 3 insufficient viable tumor cells, 6 contaminants, 5 sought other management Consistent with Phase I data in adults and Phase II data in ovarian cancer, no significant toxicity was observed in Phase I Vigil treated Ewing’s sarcoma patients. Specifically, no product related Grade 3, 4 toxic effects were demonstrated during treatment course and no long term “post treatment” toxicity has been observed.